Place of Pitavastatin in the statin armamentarium: Promising evidence for a role in diabetes mellitus

Drug Design, Development and Therapy

Volumn 5, Issue , 2011, Pages 283-297

  Kawai, Yasuyuki ^a   Sato Ishida, Ryoko ^a   Motoyama, Atsushi ^a   Kajinami, Kouji ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Diabetes mellitus; Efficacy; HMG CoA reductase inhibitor; Pitavastatin; Safety

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; WARFARIN; QUINOLINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GLUCOSE METABOLISM; HEART DISEASE; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; KIDNEY INJURY; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; PROTEINURIA; RENAL PROTECTION; REVIEW; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TINEA; ANIMAL; DRUG INTERACTION; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG INTERACTIONS; GLUCOSE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; QUINOLINES;

EID: 80052787432     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S13492     Document Type: Review

References (117)

1. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
2. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33(11):1569-1582.
3. Kimata H, Fujino H, Koide T, Yamada Y, Tsunenari Y, Yanagawa Y. Studies on the metabolic fate of NK-104, a new Inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats. Drug Metab Pharmacokinet. 1998;13(5):484-499.
4. Saito Y. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag. 2009;5: 921-936.
5. Catapano AL. Pitavastatin - pharmacological profile from early phase studies. Atheroscler Suppl. 2010;11(3):3-7.
6. ®). Nippon Yakurigaku Zasshi. 2004;123(5):349-362. Japanese.
7. Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7(3):138-144.
8. Aoki T, Nishimura H, Nakagawa S, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung. 1997;47(8):904-909.
9. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393.
10. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591.
11. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24): 2545-2559.
12. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
13. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998; 316(7134):823-828.
14. Sone H, Yamada N. Japan Diabetes Complications Study (JDCS). Nippon Rinsho. 2010;68(5):865-871. Japanese.
15. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-125.
16. Teramoto T, Sasaki J, Ueshima H, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb. 2007;14(2):45-50.
17. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51(15): 1512-1524.
18. Saito Y, Teramoto T, Yamada N, et al. Clinical Efficacy of NK- 104 (Pitavastatin), a New Synthetic HMG-CoA Reductase inhibitor, in the Dose Finding, Double Blind, Three-group Comparative Study. J Clin Ther Med. 2001;17(6):829-855. Japanese (English abstract).
19. ® Tablet)-Drug Use Investigation. Jpn Pharmacol Ther. 2007;35(1):9-40. Japanese (English abstract).
20. Hiro T, Kimura T, Morimoto T, et al; JAPAN-ACS Investigators. Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome - serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial). Circ J. 2010;74(6): 1165-1174.
21. Nomura S, Shouzu A, Omoto S, et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res. 2008;122(1):39-45.
22. Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008;201(2):345-352.
23. Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin. 2009;25(11):2755-2764.
24. Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol. 2009;4(3):291-302.
25. Rosenson RS. Management of non-high-density lipoprotein abnormalities. Atherosclerosis. 2009;207(2):328-335.
26. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20(6):1595-1599.
27. Oikawa S, Kita T, Mabuchi H, et al; J-LIT Study Group. Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT). Atherosclerosis. 2007;191(2): 440-446.
28. Teramoto T, Saito Y, Yamada N, et al. Clinical Safety and Efficacy of NK-104 (Pitavastatin), a New Synthetic HMG-CoA Reductase Inhibitor, in the Long-term Treatment of Hyperlipidemia. Results of a Multicenter Long-term Study. J Clin Ther Med. 2001;17(6):885-913. Japanese (English abstract).
29. Teramoto T, Shimano H, Yokote K, Urashima M. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb. 2009;16(5):654-661.
30. Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther. 2008;30(6):1089-1101.
31. Ose L, Budinski D, Hounslow N, Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis. 2010;210(1):202-208.
32. Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest. 2001;107(11):1423-1432.
33. Zanotti I, Favari E, Sposito AC, Rothblat GH, Bernini F. Pitavastatin increases ABCA1-mediated lipid efflux from Fu5AH rat hepatoma cells. Biochem Biophys Res Commun. 2004;321(3):670-674.
34. Kawano M, Nagasaka S, Yagyu H, Ishibashi S. Pitavastatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients. J Atheroscler Thromb. 2008; 15(1):41-46.
35. Maejima T, Yamazaki H, Aoki T, et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun. 2004;324(2):835-839.
36. Shimano H, Arai H, Harada-Shiba M, et al. Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J Atheroscler Thromb. 2008;15(3):116-121.
37. Lu W, Resnick HE, Jablonski KA, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care. 2003;26(1):16-23.
38. Watanabe N, Taniguchi T, Taketoh H, et al. Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes Care. 1999;22(1):152-156.
39. Hirano T, Ito Y, Koba S, et al. Clinical significance of small dense lowdensity lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol. 2004;24(3):558-563.
40. Yamada N, Kawazu S, Utsugi T, et al. Efficacy of pitavastatin for lipid metabolism in non-insulin-dependent diabetes mellitus. J Clin Ther Med. 2001;17(6):945-956. Japanese (English abstract).
41. Tokuno A, Hirano T, Hayashi T, et al. The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes. J Atheroscler Thromb. 2007;14(3):128-132.
42. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care. 2009;32(Suppl 2):S314-S321.
43. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007;3(6):853-876.
44. Imanishi T, Ikejima H, Tsujioka H, et al. Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. Hypertens Res. 2008;31(6): 1199-1208.
45. Ota H, Eto M, Kano MR, et al. Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arterioscler Thromb Vasc Biol. 2010; 30(11):2205-2211.
46. Sakabe K, Fukuda N, Fukuda Y, et al. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol. 2008;125(1):136-138.
47. Miyashita Y, Endo K, Saiki A, et al. Effects of pitavastatin, a 3-hydroxy- 3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb. 2009;16(5): 539-545.
48. Nasu K, Tsuchikane E, Katoh O, et al. Plaque characterisation by virtual histology intravascular ultrasound analysis in patients with type 2 diabetes. Heart. 2008;94(4):429-433.
49. Nicholls SJ, Tuzcu EM, Kalidindi S, et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol. 2008;52(4):255-262.
50. Hiro T, Kimura T, Morimoto T, et al; JAPAN-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 2009;54(4):293-302.
51. Arai H, Hiro T, Kimura T, et al; JAPAN-ACS Investigators. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome - sub-analysis of JAPAN-ACS study. J Atheroscler Thromb. 2010;17(10):1096-1107.
52. Toi T, Taguchi I, Yoneda S, et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. Circ J. 2009;73(8):1466-1472.
53. Matsuoka H, Kawakami H, Nakamura M, Komatsu J. Evaluation of Thrombi and Plaque in Saphenous Vein Graft by Angioscopy. J Jpn Coll Angiol. 2007;47:77-83. Japanese (English abstract).
54. Kodama K, Komatsu S, Ueda Y, et al. Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound - the TOGETHAR trial. Circ J. 2010;74(9): 1922-1928.
55. Nakamura T, Obata JE, Kitta Y, et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol. 2008;51(4): 365-371.
56. Honda O, Sugiyama S, Kugiyama K, et al. Echolucent carotid plaques predict future coronary events in patients with coronary artery disease. J Am Coll Cardiol. 2004;43(7):1177-1184.
57. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-2081.
58. Kimura K, Shimano H, Yokote K, Urashima M, Teramoto T. Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J Atheroscler Thromb. 2010;17(6):601-609.
59. Athyros VG, Kakafika AI, Papageorgiou AA, et al. Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. Open Cardiovasc Med J. 2007;1:8-14.
60. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care. 2005;28(11): 2728-2732.
61. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet.1982;2(8311):1309-1311.
62. Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol. 2009;5(12):713-721.
63. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21(4):473-480.
64. Ota K, Suehiro T, Arii K, et al. Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism. 2005;54(2):142-150.
65. Liang XM, Otani H, Zhou Q, et al. Renal protective effects of pitavastatin on spontaneously hypercholesterolaemic Imai Rats. Nephrol Dial Transplant. 2007;22(8):2156-2164.
66. Jin-Song HE, Horikoshi S, Funabiki K, Shirato I, Tomino Y. Effect of NK-104 on proliferation of cells. Hong Kong J Nephrol. 2001;3(2): 67-73.
67. Toyohara T, Suzuki T, Morimoto R, et al. SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol. 2009;20(12):2546-2555.
68. Ridker PM, Cannon CP, Morrow D, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20-28.
69. Arima H, Kubo M, Yonemoto K, et al. High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. Arterioscler Thromb Vasc Biol. 2008;28(7): 1385-1391.
70. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
71. Doi Y, Kiyohara Y, Kubo M, et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care. 2005;28(10):2497-2500.
72. Freeman DJ, Norrie J, Caslake MJ, et al; West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51(5):1596-1600.
73. Koshiyama H, Taniguchi A, Tanaka K, et al; Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology Investigators. Effects of pitavastatin on lipid profiles and highsensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigators. J Atheroscler Thromb. 2008;15(6):345-350.
74. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103(15):1955-1960.
75. Holvoet P, Collen D, Van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA. 1999;281(18): 1718-1721.
76. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003;41(3): 360-370.
77. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia. 2002;45(1):85-96.
78. Matsumoto T, Fujita M, Sawamura T, et al. Pitavastatin reduces lectinlike oxidized low-density lipoprotein receptor-1 ligands in hypercholesterolemic humans. Lipids. 2010;45(4):329-335.
79. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103(3): 357-362.
80. Iwai M. Effects of HMG-CoA Reductase Inhibitor, Pitavastatin on impaired glucose tolerance and vascular injury in KKAy mice. Ther Res. 2003;24(7):1329-1337. Japanese.
81. Ishihara Y, Ohmori K, Mizukawa M, Hasan AU, Noma T, Kohno M. Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice. Atherosclerosis. 2010;212(1):131-138.
82. Katayama T. Usefulness of pitavastatin on lipid profile and glucose metabolism in hypercholesterolemia with diabetes mellitus. Prog Med. 2005;25:3110-3115. Japanese.
83. Drew BG, Duffy SJ, Formosa MF, et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation. 2009;119(15):2103-2111.
84. Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care. 2005;28(3):736-744.
85. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32(10):1924-1929.
86. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742.
87. Yokote K, Saito Y; CHIBA study investigators. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). J Atheroscler Thromb. 2009;16(3):297-298.
88. Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2008;15(5):269-275.
89. Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin Pharmacother. 2010;11(5):817-828.
90. Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J Pharmacol Sci. 2008;107(1): 80-89.
91. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006;49(8):1881-1892.
92. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract. 2005; 59(2):239-252.
93. Ando H, Tsuruoka S, Yanagihara H, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol. 2005;60(5):494-497.
94. Inagaki Y, Hunt T, Arana B, Gosho M, Morgan R. Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Pitavastatin on Steady-State Warfarin in Healthy Adult Volunteers. J Clin Pharmacol. 2011. [Epub ahead of print].
95. ® Tablet)-LIVALO Effectiveness and Safety (LIVES) Study Interim (52 weeks) Report. Jpn Pharmacol Ther. 2008;36(1):9-28. Japanese (English abstract).
96. ® Tablet)-LIVALO Effectiveness and Safety (LIVES) Study. Jpn Pharmacol Ther. 2008;36(8):709-731.
97. Komano N, Masaki M, Kawai H, Kubota Y, Kajiura T. The safety and efficacy in post-marketing surveillance of atorvastatin. Prog Med. 2005;25:131-142. Japanese.
98. Yoshida S. The safety and efficacy in post-marketing surveillance of rosuvastatin. Prog Med. 2007;27:1159-1189. Japanese.
99. Orii T, Ishimoto K, Tsukamoto H, et al. The research of appropriate drug application by using pharmacoepidemiological method (Final report). J Jpn Soc Hosp Pharm. 2010;46(8):993-997. Japanese.
100. Kawashiri MA, Nohara A, Tada H, et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther. 2008;83(5):731-739.
101. SEARCH Collaborative Group, Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008;359(8):789-799.
102. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54(17):1609-1616.
103. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3): 438-445.
104. Mizuma H, Inoue T, Takano H, et al; On behalf of the PEARL Study Investigators. Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure The pitavastatin heart failure study (PEARL study). Int J Cardiol. 2010. [Epub ahead of print].
105. Kjekshus J, Apetrei E, Barrios V, et al; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-2261.
106. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231-1239.
107. Aoyagi T, Nakamura F, Tomaru T, Toyo-Oka T. Beneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failure. Int Heart J. 2008;49(1):49-58.
108. Suzuki T, Nozawa T, Sobajima M, et al. Atorvastatin-induced changes in plasma coenzyme q10 and brain natriuretic peptide in patients with coronary artery disease. Int Heart J. 2008;49(4):423-433.
109. Molyneux SL, Florkowski CM, George PM, et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol. 2008;52(18):1435-1441.
110. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A. 1985;82(3):901-904.
111. Wanner C, Krane V, März W, et al; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-248.
112. Fellström BC, Jardine AG, Schmieder RE, et al; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-1407.
113. The European Renal Association-European Dialysis and Transplant Association 2010 Congress.
114. Von Birgelen C, Hartmann M, Mintz GS, et al. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation. 2004;110(12):1579-1585.
115. Kubo M, Egashira K, Inoue T, et al. Therapeutic neovascularization by nanotechnology-mediated cell-selective delivery of pitavastatin into the vascular endothelium. Arterioscler Thromb Vasc Biol. 2009;29(6):796-801.
116. Oda S, Nagahama R, Nakano K, et al. Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia. J Vasc Surg. 2010;52(2):412-420.
117. Chen L, Nakano K, Kimura S, et al. Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension. 2011;57(2):343-350.